Clinical Trial Detail

NCT ID NCT01979536
Title Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

anaplastic large cell lymphoma

Therapies

Crizotinib

Age Groups: adult child

Additional content available in CKB BOOST